Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM
SourceBone Marrow Transplantation, 49, 1, (2014), pp. 8-10
Article / Letter to editor
Display more detailsDisplay less details
Bone Marrow Transplantation
SubjectRadboudumc 0: Other Research RIHS: Radboud Institute for Health Sciences; Radboudumc 5: Inflammatory diseases RIMLS: Radboud Institute for Molecular Life Sciences; Radboudumc 9: Rare cancers RIHS: Radboud Institute for Health Sciences
The matched-control study failed to show a clinical relevant impact of palifermin on intestinal mucositis, although there was a reduced inflammatory response and less febrile neutropenia among patients who had no bacteraemia.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.